XARELTO Market, By Indications (Nonvalvular Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Recurrent DVT or PE, Pos Knee or Hip Replacement Surgery, Venous Thromboembolism (VTE) in Acutely Ill Patients, Pediatric VTE, Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), and Post-Fontan Procedure in Congenital Heart Disease (CHD)), By Dosage Form (Tablets and Oral Suspension), By Strength (2.5 mg, 10 mg, 15 mg, 20 mg, and 1 mg/mL), By Age Group (Pediatric, Adult, and Geriatric), By Gender (Male and Female), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others (Academic and Research Institutes, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)